Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (6523)	6/22/1998 9:56:00 PM
From: aknahow	Respond to of 17367

Tharos, a great find! The new information is the existence of an adult trial. Things XOMA should tell us are: Why? When did it start? How many people will be accrued? Who asked for or wanted this trial? Did the U.K. Drs want a means of treating adults before Neuprex is approved? Is the trial open label or double blind? Why has XOMA remained silent? Is this part of the existing P III trial? Can treatment start before the adults are at stage 8 of the Glascow scale? I also think XOMA should answer all the questions I was too stupid to not ask!! <g> Again thanks for posting. I am really pissed that XOMA did not let us know immediately. I just don't understand it. Perhaps the Yahooligans are right?? Naw, I don't want to go that far. Ellen, shame on you!!!!

To: Tharos who wrote (6523)	6/22/1998 10:43:00 PM
From: Cacaito	Respond to of 17367

That's why they need 300 patients, the high and low GMSPS stratification. This requires all the groups to be about 100 each (placebo, low GMSPS and high GMSPS). This takes longer because one needs more patients. But this will assure at least one arm of the study to show results that are clinically and statistically significant. The low score should show better response, but placebo in that group will be better off too. The high score risk showing no response at all, they are worse off to start with, but We will have the milder cases to protect the ability of earlier BPI to be of worth. The safety board approval for continuation is more sensitive with the stratification. The lack of halting the data early now makes sense, there were not enough numbers at the early read of the results. Thanks Tharos.

To: Tharos who wrote (6523)	6/22/1998 11:13:00 PM
From: opalapril	Read Replies (1) \| Respond to of 17367

Terrific work, Tharos! Amazing, too. If I wore a hat it would be off to you. I do have a small request: Could you please post a citation to the source for the "notes"? Medical journal, internet site, whatever. It would be much appreciated by all, I am sure.

To: Tharos who wrote (6523)	6/23/1998 12:44:00 AM
From: LarryS	Read Replies (1) \| Respond to of 17367

Just wanted to add my thanks for your initiative...your post adds depth to our understanding of what is going on with XOMA and Neuprex. Maybe the "adults" mentioned were too old for the trial but since they showed up at the hospital (during the trial) maybe they were given Neuprex on humanitarian grounds. Especially since the doctor seems to be a believer. The trials might be stopped early in Sept but if they are not the trials will surely run thru December because we need 100 more volunteers.....once again Tharos, thank you for doing XOMA's work.